Skip to content

Aurinia Pharmaceuticals

US · AUPH #2749 by market cap Listed 1970
14.70 -0.19 -1.28%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 3.21 In line with history 46th percentile
5-year average 3.59 · #317 of 514 in Biotechnology
P/E ratio 6.90 Expensive vs history 67th percentile
5-year average 2.84 · forward 19.92 · #28 of 77 in Biotechnology
P/S ratio 6.55 In line with history 39th percentile
5-year average 10.52 · forward 5.74 · #141 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Aurinia Pharmaceuticals (AUPH) 1.97B 6.45 3.00 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value15.73 Economic moatNone UncertaintyHigh

Trading 7.0% below Morningstar's fair value estimate.

Fair value

Aurinia Pharmaceuticals Inc receives a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a price consistent with our quantitative fair value estimate, which has a high uncertainty rating.

The company's unfavorable dividend structure undermines our quantitative valuation. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. For example, the firm's forward dividend yield of 0% ranks in the bottom 30% compared with peers globally. This could imply a planned dividend cut or relatively high share price, which contributes to our balanced fair value estimate.

Alternatively, the company's profitability is reassuring. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 14.3%, for example, lies in the top 20% globally. This suggests that it is generating substantial earnings relative to its share price, which further promotes our neutral price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is fairly-valued, this outperformance had a negative impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Aurinia Pharmaceuticals discussion 0 comments

Add a comment